Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Subspecialties Cornea / Ocular Surface

Time to Say CU KC?

Glaucoma treatment may be moving away from the humble eyedrop in favor of sustained-release drugs and minimally invasive technologies, but the treatment of keratoconus could be moving towards it.

IVMED-80 is a copper-based topical treatment for keratoconus that is currently under investigation by iVeena Delivery Systems, Inc, (founded by Bala Ambati, Professor of Ophthalmology,  University of Utah, Salt Lake City, UT, USA). IVMED-80’s mechanism of action is believed to center on enhancing the activity of lysyl oxidase (LOX) – the enzyme responsible for corneal collagen crosslinking, and also known to be associated with keratoconus (1).

The essential cofactor for the enzyme? Copper. “And that led us to our hypothesis that if we supplement with copper, we could enhance LOX activity and corneal stiffening,” says Sarah Molokhia, Vice President of Research and Development at iVeena.

Applying IVMED-80 to human corneal stromal cells, the team found that LOX activity increased 10-fold in cells from keratoconic corneas, compared with a four-fold increase in normal stromal cells. They also found that human cadaver corneas treated with IVMED-80 showed improvements in radial strain. Moving to in vivo studies in New Zealand white rabbits, the team found that after four weeks of treatment, there was a flattening in corneal topography and corneal stiffness was increased (2). “We also found that our one month data was comparable with human data of UV-mediated crosslinking at six months,” says Molokhia.

The team is currently preparing for publication of their pre-clinical results, and plan to move into human trials by the end of 2018. Could patients soon be saying good-bye – or ‘C u’ – to keratoconus?

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. Y Bykhovskaya et al., “Variation in the lysyl oxidase (LOX) gene is associated with keratoconus in family-based and case-control studies”, Invest Ophthalmol Vis Sci, 53, 4152–4157 (2012). PMID: 22661479.
  2. S Molokhia. “IVMED-80 eye drops for treatment of keratoconus”. Presented at: Association for Research in Vision and Ophthalmology annual meeting; April 28–May 2, 2018; Honolulu, HI, USA.
About the Author
Ruth Steer

Related Case Studies
The Missing Piece of the Dry Eye Puzzle

| Contributed by Quidel

Uncovering Ocular Comorbidity

| Contributed by Quidel

Finding Ocular Surface Inflammation

| Contributed by Quidel

Related Product Profiles
Subspecialties Cornea / Ocular Surface
Tear Osmolarity – Empowering. Established. Essential.

| Contributed by TearLab

Subspecialties Cornea / Ocular Surface
Preservative-Free Cyclosporine 0.1% Ophthalmic Emulsion

| Contributed by ImprimisRx

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Here
Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register